<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02177292</url>
  </required_header>
  <id_info>
    <org_study_id>Prostate Cancer</org_study_id>
    <nct_id>NCT02177292</nct_id>
  </id_info>
  <brief_title>High-Dose Lymph Node Intensity Modulated Radiation Therapy and Hypofractionated Prostate (SIB)</brief_title>
  <acronym>SIB</acronym>
  <official_title>A Phase II Trial of High-Dose Pelvic Lymph Node IMRT( Intensity Modulated Radiation Therapy) and Hypofractionated Prostate IMRT for High Risk Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out the effects (good and bad) of using newer&#xD;
      technologies that allow very precise delivery of radiation. These newer technologies are&#xD;
      Intensity Modulated Radiation Therapy (IMRT) and Image Guided Radiation Therapy (IGRT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study the treating physicians will deliver a high dose of radiation to pelvic lymph&#xD;
      nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost&#xD;
      (additional) radiation to the prostate itself (to 70 Gy). The study will evaluate the&#xD;
      response of the cancer and side effects of radiation to pelvic lymph nodes and to the&#xD;
      prostate.&#xD;
&#xD;
      It is hoped that these newer technologies will:&#xD;
&#xD;
        1. allow a higher daily dose of radiation to the tumor and pelvic nodes&#xD;
&#xD;
        2. avoid nearby normal tissue and organs like the rectum and bladder&#xD;
&#xD;
        3. prevent the cancer from spreading or coming back&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2010</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA level at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>PSA level in blood is measured in units of nanograms per milliliter.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PSA level</measure>
    <time_frame>4 months</time_frame>
    <description>PSA level in blood is measured in units of nanograms per milliliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA level</measure>
    <time_frame>7 months</time_frame>
    <description>PSA level in blood is measured in units of nanograms per milliliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA level</measure>
    <time_frame>10 months</time_frame>
    <description>PSA level in blood is measured in units of nanograms per milliliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA level</measure>
    <time_frame>13 months</time_frame>
    <description>PSA level in blood is measured in units of nanograms per milliliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA level</measure>
    <time_frame>16 months</time_frame>
    <description>PSA level in blood is measured in units of nanograms per milliliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA level</measure>
    <time_frame>19 months</time_frame>
    <description>PSA level in blood is measured in units of nanograms per milliliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA level</measure>
    <time_frame>22 months</time_frame>
    <description>PSA level in blood is measured in units of nanograms per milliliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA level</measure>
    <time_frame>25 months</time_frame>
    <description>PSA level in blood is measured in units of nanograms per milliliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA level</measure>
    <time_frame>31 months</time_frame>
    <description>PSA level in blood is measured in units of nanograms per milliliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA level</measure>
    <time_frame>37 months</time_frame>
    <description>PSA level in blood is measured in units of nanograms per milliliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA level</measure>
    <time_frame>43 months</time_frame>
    <description>PSA level in blood is measured in units of nanograms per milliliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA level</measure>
    <time_frame>49 months</time_frame>
    <description>PSA level in blood is measured in units of nanograms per milliliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA level</measure>
    <time_frame>55 months</time_frame>
    <description>PSA level in blood is measured in units of nanograms per milliliter.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>IMRT &amp; IGRT Radiation Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this study we will deliver a high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>A high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).</description>
    <arm_group_label>IMRT &amp; IGRT Radiation Therapy</arm_group_label>
    <other_name>Intensity Modulated Radiation Therapy (IMRT) and Image Guided Radiation Therapy (IGRT).</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed, adenocarcinoma of the prostate&#xD;
&#xD;
          -  T1-2N0M0 with risk of pelvic lymph nodes involvement &gt;25% by Roach formula [(2/3xPSA)&#xD;
             + (Gleason Score - 6)x10], or any T3-4N0M0&#xD;
&#xD;
          -  Karnofsky Performance Scale &gt; 70.&#xD;
&#xD;
          -  Prostate tumor biopsy grading by Gleason score classification is mandatory prior to&#xD;
             registration.&#xD;
&#xD;
          -  No prior pelvic or prostate radiation or chemotherapy for any reason; induction&#xD;
             hormonal therapy prior to registration is acceptable.&#xD;
&#xD;
          -  Patients must sign a study-specific consent form prior to registration.&#xD;
&#xD;
          -  No evidence of distant metastases (Bone scanning)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical or pathological evidence of distant metastases (M1).&#xD;
&#xD;
          -  Radical surgery for carcinoma of the prostate&#xD;
&#xD;
          -  History of prior chemotherapy&#xD;
&#xD;
          -  History of prior pelvic radiation therapy&#xD;
&#xD;
          -  Children (age &lt; 18).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colleen A Lawton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CCCTO</last_name>
    <phone>414-805-8900</phone>
    <email>cccto@mcw.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Colleen A Lawton, MD</last_name>
    <phone>414-805-4472</phone>
    <email>clawton@mcw.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen A Lawton, MD</last_name>
      <phone>414-805-4472</phone>
      <email>clawton@mcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Allen Li, PhD</last_name>
      <phone>414-805-4400</phone>
      <email>ali@mcw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Colleen A Lawton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1424-30. Epub 2007 Jun 4.</citation>
    <PMID>17544601</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 18, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2014</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Colleen A. Lawton</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

